Additive Effect of Endonase on Eradication Rate of First Line Therapy for Helicobacter Pylori
Gastric Ulcer Associated With Helicobacter Pylori
About this trial
This is an interventional treatment trial for Gastric Ulcer Associated With Helicobacter Pylori focused on measuring Helicobacter pylori eradication, Peptic ulcer
Eligibility Criteria
Inclusion Criteria:
Male or Female with 18 years or more of age without history of H. pylori eradication AND
- Patients with H. pylori associated peptic ulcer in scar stage, OR
- Non-ulcer dyspepsia patients with H. pylori infection
Exclusion Criteria:
- Under 18 years, OR
- Patients with a history of previous treatment of H. pylori infection, OR
- Pregnant or Breast feeding women, OR
- Patients with severe renal, liver, or heart disease, OR
- Patients with gastric malignancy, OR
- Patients with a history of drug allergy or hypersensitivity, OR
- Patients who had received treatment with antibiotics or proton pump inhibitors, H2 Blocker, Bismuth preparation, Anticoagulant, Ketoconazole, Glucocorticoid during the 2 weeks preceding endoscopy
Sites / Locations
- Chuncheon Sacred Heart Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
PPI-based triple therapy with endonase
PPI-based triple therapy
7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week) plus 20,000 units of endonase twice daily for one week.
7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week)